John C. Cheronis
25Patents
13h-index
21Co-inventors
81Inventor score
Filing activity: May 22, 1990 → Sep 21, 2011
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6964850B2 | Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles | Emerging Cross-Sectional Technologies | 112 | Expired |
| US6692916B2 | Systems and methods for characterizing a biological condition or agent using precision gene expression profiles | Physics | 74 | Expired |
| US6004933A | Cysteine protease inhibitors | Emerging Cross-Sectional Technologies | 70 | Expired |
| US6159938A | Serine protease inhibitors comprising .alpha.-keto heterocycles | Emerging Cross-Sectional Technologies | 67 | Expired |
| US7074586B1 | Quantitative assay for low abundance molecules | Emerging Cross-Sectional Technologies | 37 | Expired |
| US5573916A | Immunogenic constructs comprising b-cell and t-cell epitopes on common carrier | Chemistry; Metallurgy | 31 | Expired |
| US6960439B2 | Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles | Emerging Cross-Sectional Technologies | 29 | Expired |
| US5416191A | Bradykinin antagonists | Human Necessities | 22 | Expired |
| US5843900A | Bradykinin antagonists | Emerging Cross-Sectional Technologies | 22 | Expired |
| US6022544A | Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry | Human Necessities | 17 | Expired |
| US6075120A | Bradykinin antagonist | Human Necessities | 17 | Expired |
| US5635593A | Bradykinin antagonists | Emerging Cross-Sectional Technologies | 16 | Expired |
| US5863899A | Bradykinin antagonists | Human Necessities | 15 | Expired |
| US5214191A | Oxidant sensitive and insensitive aromatic esters as inhibitors of human neutrophil elastase | Chemistry; Metallurgy | 8 | Expired |
| US5314910A | Ester inhibitors | Chemistry; Metallurgy | 8 | Expired |
| US5281617A | N-succinimidyl and N-phthalimidyl esters of 2-phenylalkanoic acid derivatives as inhibitors of human leukocyte elastase | Chemistry; Metallurgy | 7 | Expired |
| US5663416A | Oxidant sensitive and insensitive aromatic esters as inhibitors of human neutrophil elastase | Chemistry; Metallurgy | 7 | Expired |
| US5240956A | Ester inhibitors | Chemistry; Metallurgy | 7 | Expired |
| US5620958A | Bradykinin antagonists | Emerging Cross-Sectional Technologies | 5 | Expired |
| US7957909B2 | Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles | Emerging Cross-Sectional Technologies | 5 | Active |
| US6569876B1 | Method and structure for inhibiting activity of serine elastases | Human Necessities | 4 | Expired |
| US6375951B1 | Therapeutic suppression of specific immune response by administration of oligomeric forms of antigen of controlled chemistry | Human Necessities | 3 | Expired |
| US8055452B2 | Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles | Emerging Cross-Sectional Technologies | 2 | Active |
| US6777403B2 | Method and structure for inhibiting activity of serine elastases | Human Necessities | 2 | Expired |
| US8718946B2 | Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles | Emerging Cross-Sectional Technologies | 1 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.